Kurzfassung

Within the clinical study "Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed at least one prior line of palliative chemotherapy - The IKF/AIO Phase IIa BEMARA trial -”, the 1st medical department and the institute of pathology organize and manage the FGFR2 in-house testing as randomization strategie. The aim is to test over 900 patient samples within the study and support the scientific evaluation.
...Within the clinical study "Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed at least one prior line of palliative chemotherapy - The IKF/AIO Phase IIa BEMARA trial -”, the 1st medical department and the institute of pathology organize and manage the FGFR2 in-house testing as randomization strategie. The aim is to test over 900 patient samples within the study and support the scientific evaluation.
 » weiterlesen» einklappen